Division of GlaxoSmithKline PLC
Latest From Stiefel
Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.
Australian venture with Phase II-ready cell therapy in sights of Sumitomo Dainippon as Japanese firm looks to build regenerative medicine interests and pipeline ahead of major expiry.
India's Sun has licensed out treatments for psoriasis and dry eye to a new partner for selected Asian markets and China, which it expects to emerge as a key market for its products.
Jiangsu Hengrui’s anti-PD-1 antibody is the latest to hit the immuno-oncology market in China, ensuring a fierce battle in pricing and reimbursement. Other recent new approvals include Pfizer’s antibacterial Zavicefta and a first-in-class topical treatment for psoriasis.
- Topical Delivery
- OTC, Consumer
- Drug Delivery
- Therapeutic Areas
- Stiefel Laboratories Inc.
- Western Europe
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Barbara White, Head, Global R&D, Stiefel
Simon Jose, Pres.
Kristen B Belmonte Slaoui , PhD, VP, Bus. Dev. & Licensing
- Contact Info
980 Great West Road
Brentford, NC TW8 9GS
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.